Avon Lifesciences (India) Buy Hold or Sell Recommendation

    AVONORG -- India Stock  

    null 7.80  0.20  2.50%

    Assuming 30 trading days horizon, and your above average risk tolerance our recommendation regarding Avon Lifesciences Limited is 'Not Rated'. Macroaxis provides Avon Lifesciences buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding AVONORG positions. The advice algorithm takes into account all of Avon Lifesciences available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from AVONORG buy-and-hold prospective. Check also Trending Equities.

    Time Horizon

    Risk Tolerance

    Execute Advice
    Sell Avon LifesciencesBuy Avon Lifesciences
    Not Rated
    For the selected time horizon Avon Lifesciences Limited has a risk adjusted performance of (0.52), jensen alpha of (0.91), total risk alpha of (1.04), sortino ratio of 0.0 and treynor ratio of 10.35
    We provide buy or sell advice to complement the prevailing expert consensus on Avon Lifesciences. Our dynamic recommendation engine makes use of multi - dimensional algorithm to analyze the company potential to grow using all technical and fundamental data available at the time. To make sure Avon Lifesciences is not overpriced, please confirm all Avon Lifesciences fundamentals including its EBITDA as well as the relationship between Debt to Equity and Market Capitalization .

    Avon Lifesciences Returns Distribution Density

    Mean Return0.9Value At Risk4.98
    Potential Upside4.77Standard Deviation3.11
     Return Density 

    Avon Lifesciences Alerts

    Trading Alerts and Improvement Suggestions

    Avon Lifesciences is not yet fully synchronised with the market data
    Avon Lifesciences has high likelihood to experience some financial distress in the next 2 years
    The company has accumulated 1.3B in total debt with debt to equity ratio (D/E) of 5.75 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Avon Lifesciences has Current Ratio of 0.93 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.
    The entity reported revenue of 494.25M. Net Loss for the year was (108.42M) with loss before overhead, payroll, taxes, and interest of (8M).
    Check also Trending Equities. Please also try Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
    Search macroaxis.com